Lead-in Three real enforcement stories. Do any of these match your active portfolio or claims today?
A retinol night-cream seller on Amazon EU had a live CPNP on file. The Dutch IGJ pulled the ASIN because the EU Responsible Person had not documented SCCS's maximum retinol limits leave-on 0.3 per cent, rinse-off 0.06 per cent inside the CPSR and the outer carton did not carry the required contains retinol, avoid sun exposure warning statement.
A salicylic-acid anti-acne serum seller on Amazon US saw the ASIN suspended. VCosB matched the ingredient list against FDA limits and flagged a 2.8 per cent salicylic acid leave-on plus AHAs formulation that exceeded the 2 per cent SA VCosB guidance. FDA MoCRA cross-checking triggered a recall-level review.
A botanical whitening-serum seller on Rakuten Japan saw the container held in customs. They had not submitted a Foreign Manufacturer (FMMF) notification to MHLW. Worse, both arbutin and 4-MSK (4-methoxysalicylate potassium) sit on the Japanese quasi-drug approved active list but the SKU was declared only as a cosmetic. MHLW rejected entry until a quasi-drug approval route was opened.
The three core frameworks are not variants of one filing. The EU mandates RP plus CPSR; the US enforces post-market surveillance plus MoCRA GMP; Japan enforces manufacturing notification plus a quasi-drug / cosmetic divide
A very common costly assumption is that three markets are the same ingredient report translated. The legal frameworks and enforcement triggers are entirely different:
| Dimension | European Union (EEA incl. | United States | Japan | Primary legislation | EC 1223/2009 Cosmetic Regulation + SCCS scientific opinions + CLP classification & labelling | FD&C Act, Fair Packaging & Labeling Act + 2025 Modernization of Cosmetics Regulation Act (MoCRA) | Pharmaceuticals and Medical Devices Act (PMD Act, formerly Pharmaceutical Affairs Law) + Cosmetic Standards + Quasi-Drug Raw Material . | Responsible person | Mandatory EEA-based Responsible Person (RP), real physical office, accountable for compliance and SCNI (Serious Cosmetic Non-compliance . | Mandatory US Agent for FDA registration purposes. MoCRA makes the Responsible Person explicitly accountable for retaining Serious Adverse . | Mandatory Japanese Licensed Marketing Authorisation Holder (MAH). Since the 2020 PMD Act amendment, overseas factories may additionally file . | Product-level filing | Mandatory CPNP (Cosmetic Products Notification Portal) pre-market filing per SKU; CPNP number generated. | Historically voluntary VCRP. Under MoCRA, facility registration + cosmetic product listing are both mandatory, run on parallel systems. | Ordinary cosmetics: pre-market Marketing Notification (formal MHLW pre-launch filing). | Safety dossier | Mandatory CPSR (Cosmetic Product Safety Report), Part A (product info) + Part B (safety assessment), signed by EU-qualified Safety Assessor, . | No mandated CPSR format, yet MoCRA explicitly requires Responsible Person to retain substantiation of safety evidence file: toxicology . | Mandatory PSQR, Quality and Safety Information compilation dossier: ingredient specifications, toxicology, preservative challenge data, . | Ingredient lists | Annex II banned / Annex III restricted; Annex IV colorants, Annex V UV filters, Annex VI preservatives; 1,300+ entries. | VCosB ingredient DB + INCI dictionary + FDA GRAS determinations + OTC Monographs (any SPF, anti-acne, anti-dandruff, antiperspirant claim = . | Cosmetic Standards Appendix ~2,000 acceptable ingredients. Quasi-Drug Raw Material Specs 2020 approved active ingredients. | Label & INCI language | Mandatory INCI names; at least one official Member State language + English optional; expiry, batch, country of origin, all warnings. | Mandatory INCI, net contents on PDP in oz + g/ml dual units; full Drug Facts panel if classified OTC Drug. | Full Japanese component names (Cosmetic Ingredient Naming List) or INCI + Japanese gloss. | GMP / production norms | de-facto mandatory ISO 22716 or equivalent GMPC; expected at any market surveillance audit. | MoCRA makes GMP explicitly mandatory from 2025, aligned to ISO FDA can physically inspect overseas factories. | MHLW Cosmetics GMP Ministerial Ordinance applicable since Japanese domestic manufacturing sites must hold MHLW approved-plant status. | Claims perimeter | EU 655/2013 common criteria. no disease-treatment claims. any efficacy claim needs adequate substantiation. | FDA forbids disease-treatment claims. SPF, anti-acne, anti-dandruff, antiperspirant and skin-bleaching claims automatically move the SKU into . | Strict ordinary-cosmetic 56-item allowed-effect list. Any whitening, anti-wrinkle, acne-prevention, hair-growth, tooth-whitening claim . |
|---|
Five high-enforcement actives side-by-side: EU vs US vs Japan limits, warnings and classification calls
Retinol (vitamin A), salicylic acid (BHA), ascorbyl tetraisopalmitate (VC-IP) and other vitamin-C esters, chemical UV filters (oxybenzone, octocrylene, avobenzone families) and botanical whitening actives (arbutin, glabridin, 4-MSK, resorcinol derivatives) together account for the overwhelming majority of platform and customs hold cases:
| Active / family | European Union | United States | Japan | Retinol / vitamin A | SCCS Opinion: leave-on ≤0.3%, rinse-off ≤0.06%. Vitamin A total RE equivalents (Retinol, RAL, RAcetate, RPalmitate combined) recommended . | Ordinary skincare use non-OTC at common practical levels up to ~2 per cent. strong anti-acne or anti-wrinkle + high-concentration positioning . | Ordinary cosmetic cap ≤0.1%. Any explicit anti-wrinkle or anti-acne efficacy claim moves the SKU into the Quasi-Drug approval route; the . | Salicylic acid (BHA) | Annex III item 44: leave-on ≤2%, rinse-off ≤3%; forbidden on children under three except hair shampoos. | VCosB practice: leave-on SA + AHA total ≤5% and final pH ≥3.5. anti-acne / keratolytic claims trigger OTC Drug rules. | Ordinary cosmetic ≤2%. acne-focused quasi-drug formulations ≤0.5%, separate quasi-drug regulatory approval required. | Chemical UV filters (Oxybenzone, Avobenzone, Octocrylene, etc.) | Only Annex V whitelisted UV filters permitted. benzophenone-3 ≤6%, octocrylene ≤10%, avobenzone ≤3%. | Only 16 UV filters inside the FDA Sunscreen OTC Monograph can carry SPF claims; some EU-popular filters (Mexoryl SX) remain unapproved in the US. | Only 30 approved UV absorbers inside the 2020 Quasi-Drug Raw Material Specs item 307 UV-absorber list; anything outside is non-permissible. | 4-MSK, arbutin, tranexamic-acid whitening actives | None sit inside the EU CosReg banned/restricted annexes as such, but any whitening or depigmentation claim triggers a full SCCS-style safety . | Skin bleaching claim moves directly to OTC Drug classification; only hydroquinone has a recognised OTC monograph skin-bleaching route. | These three actives are part of the top-five recognised Japanese quasi-drug whitening active list (4-MSK, arbutin, tranexamic acid, kojic acid,. | Botanicals, essential oils, liquorice, glabridin, chamomile, tea tree | 2023 SCCS 15 fragrance-allergen disclosure rule: leave-on >0.001% and rinse-off >0.01% of limonene, linalool, citronellol, geraniol and 11 . | FDA has no positive botanical whitelist; high-risk components inside essential oils (camphor, methyl salicylate etc.) receive warning letters . | Subject to both Cosmetic Standards and Cosmetic Ingredient Specifications lists; from April 2026, novel botanical extracts undergo a new PCR . |
|---|
🛑 Critical red flag. The whitening and anti-wrinkle claim perimeters in Japan are hard lines. Ordinary cosmetics in Japan may not use terms such as bihaku whitening, shimi yobo spot prevention, shiwa kaizen wrinkle improvement, nikibi yobo acne prevention, ikumo hatsumo sokushin hair growth promotion or ha o shiroku suru tooth whitening.
Even if the formulation does not contain a recognised quasi-drug active, the JFTC (Fair Trade Commission) and MHLW pharmaceutical surveillance teams will still open an enforcement action on the claim alone. More than 57 per cent of the 120+ Japan beauty cases handled by a were claim-boundary stops, not concentration breaches.
EU operational rollout: how to choose the RP, how to populate CPNP, how to build the CPSR and what triggers IGJ or BfArM audits
🔹 EU Responsible Person. The RP must have a genuine physical EEA office, not a postal drop box. They hold every SKU's CPSR, the PIF Product Information File and the serious undesirable effect (SUE) log. Do not select trading companies or 3PL operations as the RP. Choose a team with actual cosmetic-regulatory lawyers or DipCF-qualified assessors on staff. If an IGJ request arrives and the RP cannot produce a complete CPSR within 48 hours, all connected SKUs are routinely pulled from market.
🔹 CPNP filing mechanics. File a separate CPNP number per genuine SKU (variations in fragrance, size or format = distinct SKUs). Data pillars: RP details, brand, product name, category, fragrance allergens declared, Annex VI preservatives, Annex V UV filters, Annex IV colorants, any nanomaterial declarations (nano TiO2, nano ZnO require their own datasets), country of origin and intended import Member States.
🔹 CPSR two halves. Part A, the PIF, captures: formula, raw material COAs, microbiological limits testing, preservative efficacy challenge testing (CT/M-1/2 or ISO 11930), stability & compatibility, packaging migration testing on contact materials, heavy metals (As,Pb,Hg,Cd,Sb,Ni), 1,4-dioxane, free-formaldehyde donors and 6P phthalates. Part B, the Safety Assessment, must be signed by an EU-recognised Cosmetic Safety Assessor (DipCF, PharmD, Toxicology MSc + relevant years of experience). It scores dermal, ocular, sensitisation, phototoxicity and genotoxicity exposure and produces systemic absorption estimates for each restricted ingredient.
🔹 Common audit triggers. A fresh SCCS Opinion (e.g., tightened retinol limits or the 2023 fragrance-allergen expansion) automatically flags every relevant CPNP entry for national re-review. Consumer reports of serious adverse effects route IGJ or BfArM inspectors to the RP's PIF repository. Platform AI keyword scans for medical grade, barrier repair, spot-removal or other medical-style claims trigger an immediate CPSR Part B substantiation demand.
✅ Practical shortcut from a . Before CPNP submission, run every raw material against the EU Annexes one-by-one: Annex II banned, Annex III restricted, Annex IV colours, Annex V UV filters, Annex VI preservatives. For every Annex III restricted hit, confirm the concentration cap AND the mandatory warning label are both correct.
For every nanomaterial UV filter hit, confirm the nano label wording, particle size distribution dataset and Part B safety assessment exist together. This self-check resolves more than 85 per cent of CPNP rejection issues before you press submit.
US MoCRA operational rollout: facility registration, product listing, SAE reporting and GMP must operate as a single integrated system
🔹 FDA Establishment Registration. Post-MoCRA (effective 29 Dec 2025), every cosmetic manufacturing facility globally, including OEM/ODM own-brand factories, must hold an FDA FEI Establishment Registration Number. Renew biennially (even-numbered years).
🔹 Cosmetic Product Listing (CPL). MoCRA requires every cosmetic SKU product listing within 120 days of marketing. Upload INCI formula details including fragrances, colorants and nanomaterials into the new FDA system. The VCosB database runs in parallel to allow automated FDA cross-check against GRAS, banned-restricted and OTC monograph lists. Out-of-range salicylic acid concentrations are therefore frequently flagged algorithmically by VCosB matching before a physical customs exam ever takes place.
🔹 Serious Adverse Event (SAE) reporting. Under MoCRA the Responsible Person must submit a MedWatch 3500A report within 15 business days of learning of any SAE (burns, disfigurement, hospital admission, anaphylaxis, miscarriage etc.). Retain SAE logs for six years.
🔹 MoCRA GMP compliance. GMP, aligned largely to ISO 22716, is now explicitly mandated. FDA may physically inspect overseas plants. A non-conforming inspection can activate FDA Import Alert #66-38 causing automatic detention-at-port of every SKU produced at the facility.
🔹 OTC vs cosmetic boundary. Any product claiming SPF sun protection, anti-acne, anti-dandruff action, fluoride anti-caries toothpaste effect or antiperspirant efficacy is classified by definition as an OTC Drug, not an ordinary cosmetic. It must follow the applicable OTC Monograph or NDA pathway; cosmetic-only registration is insufficient and a known MoCRA enforcement priority.
Japan PMD Act operational rollout: the ordinary-cosmetic vs quasi-drug split decides everything, plus the FMMF + MAH two-piece package
🔹 Split the SKU on day one into ordinary cosmetic vs quasi-drug. Use the two-line test: does the formulation contain any MHLW recognised Quasi-Drug Approved Active (4-MSK, tranexamic acid, arbutin, dipotassium glycyrrhizinate, piroctone olamine etc.) OR does the marketing copy carry a whitening, anti-wrinkle, acne prevention, hair-growth, anti-caries or deodorant-bactericidal claim. If either line returns yes the SKU must go down the MHLW Quasi-Drug Approval route (review 6-18 months). If both lines return no it falls under ordinary cosmetic notification, typically completable in about one month.
🔹 FMMF Foreign Manufacturer Notification. After the 2020 PMD Act amendments, overseas cosmetics factories may file the FMMF (Foreign Cosmetic Manufacturer Notification) directly with MHLW. The registration documents identify the overseas plant, address, product scope, GMP responsible officer and inspection system. From 2025 onward, Amazon.co.jp, Rakuten and Yahoo Shopping treat an active FMMF registration number as a baseline gatekeeping condition for new SKU listings.
🔹 Japanese Marketing Authorisation Holder (MAH). Even with a valid FMMF, a Japan-based company holding a Cosmetic Marketing Authorisation Business Licence must still be appointed. They take full domestic compliance accountability: PSQR dossier retention, serious side-effect reporting, batch-level recall co-ordination and MHLW liaison. Think of them functionally as the Japanese version of the EU RP.
🔹 Label and claims. Japanese-only labels must show: product name, MAH or Import Declaration Holder name & address, lot number or code, expiry date only if shelf life under three years unopened, full ingredient names matching the Cosmetic Ingredient Naming List, usage precautions and country of origin. The allowed-efficacy list for ordinary cosmetics contains exactly 56 items; inventing your own efficacy language is not permitted.
🔹 Enforcement mechanics. MHLW pharmaceutical surveillance officers sample bonded-warehouse consignments, test ingredient conformance and verify label compliance. Non-conformance triggers either immediate import prohibition or hold-and-resolve-then-reinspect. Platform side, MHLW feeds an in-house violation SKU feed to Amazon, Rakuten etc.; one enforcement hit on a SKU moves every other SKU under the same brand into a high-risk scan bucket.
Closing cosmetics compliance is not a registration form; it is an ongoing three-pillar programme across ingredient safety, accountable responsibility and market-access documentation
The costliest cosmetics compliance mistake is to equate filing the CPNP, VCRP-style listing or FMMF notification with full compliance. Filing gets you the first entry ticket only. What actually keeps goods through customs, platform reviews and market surveillance audits are the two pillars behind the ticket: accurate classification of every active ingredient with respect to each market's concentration cap, warning language and OTC or quasi-drug status; an RP or MAH that can produce the complete CPSR/PSQR/PIF and adverse-event four-piece dossier within 48 hours when an auditor calls.
Too many teams select the cheapest possible form-filling service for CPNP submission and then discover, during the first real audit, that they hold no signed Part B assessment conclusions and no raw material traceability which typically ends with the entire brand's EU or Japan storefront suspended.
If your team is stuck today on classifying restricted actives inside formulas, deciding whether a whitening SKU needs Japanese quasi-drug approval, selecting the EU RP or scoping the MoCRA registration timelines and CPSR-PIF differences, send us the INCI formulas, SKU list, any existing certificate or report packages and screenshots of the target-market claim pages right now.
a provides end-to-end three-market compliance: INCI-to-market banned-restricted ingredient matrix red-line review covering the five high-risk active families with classification, cap and warning suggestions; EU RP introduction, CPSR & PIF dossier build, CPNP filing and IGJ/BfArM audit-response management; US FDA facility registration, mandatory product listing, VCosB cross-check, MoCRA GMP gap remediation and SAE 15-business-day reporting process implementation; Japan FMMF notification, MAH responsible-party framework establishment, ordinary-cosmetic vs quasi-drug bifurcation determination, quasi-drug approval consulting, full Japanese INCI naming and the full PSQR dossier package.
a has supported 120+ beauty and skincare brands through EU, US and Japan compliance reviews, including four Amazon Top-15 beauty brands and nine Rakuten Beauty Gold-tier sellers, with a >95 per cent CPSR audit pass rate, >98 per cent MoCRA facility+listing one-pass rate and, on quasi-drug approval files, an average three-month reduction in MHLW review timelines over the last 18 months.
a maintains ready-to-use EU Annex II-VI databases, a US OTC Monograph + VCosB cross-matching template and a Japanese Quasi-Drug Active List + 56-item Allowed-Efficacy matrix that plug straight into your SKU bifurcation exercise; a bifurcation report can typically be delivered in ten working days.
a also aggregates OEM/ODM ISO 22716, raw material COAs, challenge tests and patch-test data into a shared evidence pool feeding the EU CPSR, the Japanese PSQR and the US MoCRA safety file in parallel, eliminating duplicate documentation requests and spend.
